Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2023-03-21 |
2022-12 |
-2.46 |
N/A |
N/A |
N/A |
2022-11-14 |
2022-09 |
-1.51 |
N/A |
N/A |
N/A |
2022-08-11 |
2022-06 |
-1.29 |
N/A |
N/A |
N/A |
2022-05-10 |
2022-03 |
-0.75 |
N/A |
N/A |
N/A |
2022-03-15 |
2021-12 |
0.1 |
N/A |
N/A |
N/A |
2021-11-11 |
2021-09 |
0.15 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2021-12-09 |
Oppenheimer |
Upgrade |
|
Outperform |
2018-09-28 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2018-06-12 |
Cantor Fitzgerald |
Upgrade |
|
Overweight |
2012-11-30 |
Mizuho |
Downgrade |
Buy |
Neutral |
2018-05-05 |
B. Riley FBR |
Downgrade |
Buy |
Neutral |
2012-10-31 |
Evercore Partners |
Downgrade |
Overweight |
Equal-Weight |
Date |
Name |
Relation |
Quantity |
Description |
2022-06-13 |
COLLARD CRAIG A |
Director |
55.82K |
Stock Award(Grant) |
2023-01-26 |
CRYSTAL ROGER |
Chief Executive Officer |
75.34K |
Sale |
2022-06-13 |
DALY RICHARD J |
Director |
7.80K |
Stock Award(Grant) |
2023-01-26 |
ELLISON MARK JASON HEATH |
Officer |
18.75K |
Sale |
2023-01-26 |
GORMAN BRIAN |
General Counsel |
31.99K |
Sale |
2023-01-26 |
O'TOOLE DAVID D |
Chief Financial Officer |
34.25K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-12-30 |
Western Standard, LLC |
424.08K |
8.76M |
15.02% |
2022-12-30 |
Apis Capital Advisors, LLC |
214.00K |
4.42M |
7.58% |
2022-12-30 |
Morgan Stanley |
197.65K |
4.08M |
7.00% |
2022-12-30 |
Vanguard Group, Inc. (The) |
190.77K |
3.94M |
6.76% |
2022-12-30 |
Renaissance Technologies, LLC |
146.42K |
3.02M |
5.19% |
2022-12-30 |
Wells Fargo & Company |
136.81K |
2.83M |
4.85% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-09-29 |
Vanguard Total Stock Market Index Fund |
120.26K |
2.48M |
4.26% |
2022-09-29 |
Vanguard Extended Market Index Fund |
62.25K |
1.29M |
2.21% |
2022-12-30 |
IndexIQ Tr-IQ Merger Arbitrage ETF |
61.91K |
1.28M |
2.19% |
2022-10-30 |
DFA U.S. Targeted Value Portfolio |
29.51K |
609.32K |
1.05% |
2022-11-29 |
Fidelity Extended Market Index Fund |
27.81K |
574.19K |
0.99% |
2022-10-30 |
DFA U.S. Small Cap Series |
18.27K |
377.34K |
0.65% |
Split |
Date |
1 : 100 |
2014-12-31 |